Abstract 4773: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways
S. Michael Rothenberg(Pfizer (United States)), Daniel A. Haber(Howard Hughes Medical Institute), Jeffrey A. Engelman(Cancer Research Center), Sarah Cullen(University of Arkansas for Medical Sciences), Anthony C. Faber(Virginia Commonwealth University), Shyamala Maheswaran(Massachusetts General Hospital), Alexa B. Turke(Harvard University), Kyle Concannon(Harvard University)
Cited by 0